Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1-2
|
| pubmed:dateCreated |
1995-7-10
|
| pubmed:abstractText |
Forty-five patients with stage III-IV low grade non-Hodgkin's lymphoma (NHL) were treated with a non-intensive polychemotherapy regimen including chlorambucil-vincristine and cytarabine (Ara-C), termed COA, for a total of 366 courses, beginning in June 1986. Grade 4 myelotoxicity occurred in only 4/45 patients. No treatment related death was observed. All patients were evaluable for response. Overall, 38 (84%) objective responses, including 31 (69%) complete responses (CR), were observed. At a median follow-up of 57 (21-84+) months, only 8 deaths occurred. Twenty-seven (60%) patients are still disease-free. All disease-free patients were in their first CR. The seven-year estimated survival is 71% and the estimated 7-year progression-free survival (PFS) was 48%. The estimated probability of complete responders to be disease-free at 6 years is 78%. Pretreatment laboratory parameters (serum levels of thymidine kinase, LDH and TNF-alpha showed a good prognostic relevance at using univariate analysis. At multivariate analysis, only the pretreatment serum levels of TNF-alpha were significantly associated with a higher CR achievement probability (p = 0.02) and a longer PFS (p = 0.02). We established a risk model for clinical outcome based on these 3 parameters. Patients having all parameters within the normal range at diagnosis, showed a very good prognosis (100% 7-year PFS and survival), while patients with all parameters increased had a very poor prognosis (0% 7-year PFS and 22% 7-year survival). In conclusion, COA treatment appears to be a non-toxic and very effective treatment for low-grade non-Hodgkin's lymphomas.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Chlorambucil,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidine Kinase,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1042-8194
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
147-53
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7773152-Adult,
pubmed-meshheading:7773152-Aged,
pubmed-meshheading:7773152-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7773152-Chlorambucil,
pubmed-meshheading:7773152-Cytarabine,
pubmed-meshheading:7773152-Evaluation Studies as Topic,
pubmed-meshheading:7773152-Female,
pubmed-meshheading:7773152-Humans,
pubmed-meshheading:7773152-Lymphoma, Non-Hodgkin,
pubmed-meshheading:7773152-Male,
pubmed-meshheading:7773152-Middle Aged,
pubmed-meshheading:7773152-Predictive Value of Tests,
pubmed-meshheading:7773152-Prognosis,
pubmed-meshheading:7773152-Quality of Life,
pubmed-meshheading:7773152-Thymidine Kinase,
pubmed-meshheading:7773152-Tumor Markers, Biological,
pubmed-meshheading:7773152-Tumor Necrosis Factor-alpha,
pubmed-meshheading:7773152-Vincristine
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas.
|
| pubmed:affiliation |
Cattedra di Oncologia Medica, Facoltà di Medicina, Università di Cagliari, Napoli, Italia.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|